Saturday, December 3, 2022


Biotechnology News Magazine

Cytel Designed & Led TOGETHER Trial Wins Society of Clinical Trial’s David Sackett Trial of the Year Award

Latest Posts

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care.

Acer Therapeutics Announces $1.5M Private Placement

The proceeds from the private placement will be used by Acer Therapeutics for working capital and general corporate purposes and, together with Acer’s existing cash and cash equivalents, are expected to be sufficient to fund the Company’s anticipated operating and capital requirements through the fourth quarter of 2022.

AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The selection of ACI-35.030 for further development is a significant step for this collaboration. Early clinical testing showed that ACI-35.030 was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and enriched paired helical filaments (ePHF) species, both of which are closely implicated in Alzheimer’s disease (AD).

TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors

The planned clinical trial is to evaluate TransCode’s lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode Therapeutics believes that TTX-MC138 could be used as a treatment for many of these cancers.

The TOGETHER Trial for COVID-19 therapies, designed by clinical trial specialists at Cytel Inc., has just won the Society for Clinical Trial’s annual Trial of the Year Award for 2021.

Designed with the view to rapidly test cost-effective therapies for low-income communities, the TOGETHER Trial used advanced statistical expertise to reach accelerated testing of eleven interventions, along with the deployment of clinical research infrastructure that will ensure that low-income communities can quickly find cost-effective therapies in the future. Since its launch nearly two years ago, TOGETHER has enrolled over 6000 patients in 22 research sites in Brazil.  It is now expanding to Pakistan and South Africa, Rwanda, DRC and Vietnam.

Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills. “We have a moral responsibility to ensure that COVID-19 therapies are both effective and accessible to the majority of people,” says Dr. Mills, “In a rush to find therapies that work, members of the global community failed to recognize that much of the world would not be able to afford a number of the therapies initially put forward for examination. Members of the TOGETHER Trial joined to ensure that low- and middle-income countries did not miss out on the global search for effective results. I see the recognition from SCT as a recognition of global scientific cooperation.”

The David Sackett Trial of the Year Award, named for the scientist long thought of as the father of evidence-based medicine, has been given every year since 2008. Award winning trials have to meet five critical standards of impact: the trial must improve the lot of humanity; a trial must offer a substantial, beneficial change in healthcare; the trial reflects expertise in both subject-matter and trial design while demonstrating concern for patients; the trial overcomes obstacles in implementation; and scientists working on the trial can provide a presentation of design, execution and results, that is a model of clarity and intellectual soundness.

Reflecting on the achievement, Josh Schultz, CEO of Cytel noted, “We are committed to designing clinical trials for human impact, and always appreciate being the strategic partner for those with visionary ideas for how new medicines, should get to patients faster. Our combination of innovative software, data resources, services capabilities and of course scientific expertise, partner together to make these unique and impactful trials possible.”

One of the challenges in COVID-19 response has been the typical multiyear timeframe it normally takes to secure scientific validity of clinical trial results. Using a design called a multi-arm adaptive platform trial, Cytel’s statisticians were able to shorten this time horizon from years to months, without compromising on scientific integrity.

According to Dr. Radek Wasiak, the head of Real World Evidence at Cytel Inc., “It was extraordinary to see scientists in the USA, Brazil, South Africa and Pakistan working in tandem to share results and generate solutions more quickly. TOGETHER Trial proves that the massive power of the private sector can be channeled towards these trials which were originally considered too complicated or high-risk for the private sector to coordinate.”

This study has been funded by FTX Foundation, the Bill & Melinda Gates Foundation, the Rainwater Charitable Foundation and FastGrants. More here.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine